ORTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Jan 2024 @ 16:00):

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...

Stats
Today's Volume	372 349
Average Volume	105 224
Market Cap	380.11M
EPS	$0 ( 2024-03-04 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.07
ATR14	$0.0590 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Secor Alicia	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Secor Alicia	Sell	105 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	44 391	Ordinary Shares
2024-01-24	Geraghty James A	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	105 000	Stock Option (Right to Buy)

INSIDER POWER
-30.53
Last 99 transactions
Buy: 13 341 271 \| Sell: 6 351 136

Volume Correlation

Long: 0.03 (neutral)

Short: 0.00 (neutral)

Signal:(85.364) Neutral

Orchard Therapeutics PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orchard Therapeutics PLC Correlation - Currency/Commodity

0.74
( moderate )

0.87
( strong )

0.71
( moderate )

-0.20
( neutral )

0.77
( moderate )

-0.75
( moderate negative )

Orchard Therapeutics PLC Financials

Annual	2022
Revenue:	$6.99M
Gross Profit:	$4.55M (65.17 %)
EPS:	$-0.610

Q3	2023
Revenue:	$6.30M
Gross Profit:	$4.56M (72.31 %)
EPS:	$-1.550

Q2	2023
Revenue:	$7.31M
Gross Profit:	$5.13M (70.07 %)
EPS:	$-0.650

Q1	2023
Revenue:	$1.24M
Gross Profit:	$870 000 (70.33 %)
EPS:	$-1.230

Financial Reports:

No articles found.

Orchard Therapeutics PLC

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.